These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 5034697

  • 1. Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.
    Barbeau A, Mars H, Botez MI, Joubert M.
    Can Med Assoc J; 1972 Jun 10; 106(11):1169-74. PubMed ID: 5034697
    [Abstract] [Full Text] [Related]

  • 2. [Treatment of Parkinson's disease with L-dopa alone or combined with Ro 4-4602].
    Barbeau A, Gillo-Joffroy L, Mars H, Arsenault A.
    Rev Can Biol; 1972 Jun 10; 31():Suppl:169-74. PubMed ID: 5052323
    [No Abstract] [Full Text] [Related]

  • 3. [Clinical studies on the treatment of parkinsonism with the L-dopa and decarboxylase inhibitor Ro-4-4602 association].
    Wajsbort J, Hemli JA, Alfandary I, Yahel M, Siegfried J.
    Wien Med Wochenschr; 1971 Oct 16; 121(42):741-5. PubMed ID: 5115985
    [No Abstract] [Full Text] [Related]

  • 4. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ, Somerville B.
    Med J Aust; 1974 Mar 23; 1(12):429-32. PubMed ID: 4598384
    [No Abstract] [Full Text] [Related]

  • 5. [Therapy of Parkinson's syndrome with L-dopa per os combined with a decarboxylase inhibitor (Ro 46.02)].
    Tissot R, Gaillard JM, Guggisberg M, Gauthier G, De Ajuriaguerra J.
    Neurol Neurocir Psiquiatr; 1969 Mar 23; 10(1):1-25. PubMed ID: 5406970
    [No Abstract] [Full Text] [Related]

  • 6. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R, Gaillard JM, Guggisberg M, Gauthier G, de Ajuriaguerra J.
    Presse Med (1893); 1969 Apr 05; 77(17):619-22. PubMed ID: 5785081
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R, de Ajuriaguerra J.
    Nouv Presse Med; 1973 Feb 03; 2(5):315-6. PubMed ID: 4686226
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa.
    Fermaglich J.
    Med Ann Dist Columbia; 1974 Dec 03; 43(12):587-91. PubMed ID: 4532167
    [No Abstract] [Full Text] [Related]

  • 14. [Two years experience with L-DOPA in association with a decarboxylase inhibitor].
    Siegfried J.
    Rev Neurol (Paris); 1970 Apr 03; 122(4):243-8. PubMed ID: 5472041
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
    Rondot P.
    Rev Prat; 1974 Mar 11; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M, Miwa H, Kondo T.
    No To Shinkei; 2002 Feb 11; 54(2):127-32. PubMed ID: 11889758
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.